“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Progressing towards the development of
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Lupin wins India Packaging Award for ‘Corcal Bone & Beauty’
Mumbai, May 29, 2019: Pharma major Lupin Limited (Lupin) announced today that it has won the India Packaging Award 2019 for its Consumer Healthcare brand ‘Corcal Bone & Beauty’, a calcium supplement specially for women. Corcal is the latest launch by the company’s Consumer Healthcare Business, LupinLife. The India Packaging Award was received for the category ‘Excellence in Packaging Design – Graphics and Brand Value Add’ by UBM India.
Speaking on the win Mr. Anil V. Kaushal, Head – LupinLife Consumer Healthcare, Lupin Limited said, “We would like to thank the jury of ‘India Packaging Award 2019’ for recognising our efforts in making the packaging appealing and convenient for our customers. The packaging of Corcal Bone & Beauty has been specifically designed to create a visual appeal basis rigorous consumer research. For us, winning the award is a great honor and it demonstrates our level of commitment to excellence and design while keeping in mind quality, safety and compliance requirements.”
About Corcal Bone & Beauty
LupinLife’s Corcal Bone & Beauty contains natural Coral Calcium and over 70 trace minerals like Zinc, Selenium, Gold, Magnesium, and Silica. The product helps maintain healthy skin, hair, nails & teeth and strong bones.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company by revenues (31st Dec 2018, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Mar 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Dec 2018, Bloomberg LTM); 5th largest company in the Indian Pharmaceutical Market and 6th largest generic pharmaceutical player in Japan (IQVIA MAT Mar 2019).
For the financial year ended 31st March 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
VP – Corporate Communications
Ph: +91-22-66402531 / 8291013225
Head – Investor Relations
Safe Harbor Statement